Viewing Study NCT06368908



Ignite Creation Date: 2024-05-06 @ 8:23 PM
Last Modification Date: 2024-10-26 @ 3:27 PM
Study NCT ID: NCT06368908
Status: RECRUITING
Last Update Posted: 2024-04-16
First Post: 2024-04-09

Brief Title: Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill
Sponsor: General and Teaching Hospital Celje
Organization: General and Teaching Hospital Celje

Study Overview

Official Title: Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill
Status: RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: FMS_ICU
Brief Summary: ICU-Acquired weakness ICU-AW is a significant complication of critical illness ICU-AW is common in patients with sepsis systemic inflammatory response and mechanically ventilated It is estimated that around 50 of patients recovering from the primary illness remain in intensive care with characteristic muscle weakness This leads to dependence on mechanical ventilation prolonging costly intensive care hospitalization The myopathy causes persistent functional impairment endangering patients long after hospital discharge

Magnetic stimulation prevents inactivation atrophy of skeletal muscles as demonstrated in the mobilized limb of rats Transcutaneous magnetic stimulation of the quadriceps via the femoral nerve is a safe and painless method even when applied to humans

In patients with chronic obstructive pulmonary disease COPD quadriceps magnetic stimulation increased spontaneous contraction force compared to the control group and improved quality of life Patients with COPD tolerate quadriceps magnetic stimulation well as it does not affect oxidative stress in muscles but does increase the size of slow-twitch muscle fibers

In intensive care medicine magnetic stimulation has been primarily used for diagnostic purposes in assessing diaphragm function peripheral muscle strength assessment and transcranial electrical stimulation as a diagnostic tool and therapeutic stimulation of brain cells With the development of modern transcutaneous magnetic stimulators the possibility arises for their use in intensive care medicine for therapeutic purposes such as preventing critical illness myopathy

To date no research has been conducted on the use and effectiveness of magnetic stimulation of peripheral muscles in critically ill individuals

The aim of the study is to investigate the effect of Functional Muscle Magnetic Stimulation FMS on the development of ICU-AW
Detailed Description: 1 Introduction

ICU-Acquired weakness ICU-AW is a significant complication of critical illness ICU-AW is common in patients with sepsis systemic inflammatory response and mechanically ventilated It is estimated that around 50 of patients recovering from the primary illness remain in intensive care with characteristic muscle weakness This leads to dependence on mechanical ventilation prolonging costly intensive care hospitalization The resulting myopathy causes persistent functional impairment endangering patients long after hospital discharge

11 Pathophysiological basis of development of Critical illness myopathy The pathophysiological mechanisms of ICU-AW are poorly understood leading to the absence of specifically targeted treatments for its prevention In most patients skeletal muscle atrophy is observed particularly the loss of fast-twitch muscle fibers type II and decreased levels of myosin heavy chains MyHC The loss of MyHC is a consequence of disrupted balance between its synthesis and degradation The most significant contributors to the development of ICU-AW include systemic inflammation sepsis immobilization sedation hyperglycemia exposure to neuromuscular blocking agents and corticosteroids resulting in decreased muscle mass and strength The principal intracellular system for protein degradation in skeletal muscles is the ubiquitin-proteasome system which also regulates MyHC degradation

12 Physiotherapy and Transcutaneous Electrical Muscle Stimulation Therapeutic activity in the intensive care unit often begins with passive mobilization especially in inactive and unconscious patients In the treatment of critically ill patients is aimed to reduce sedation providing appropriate analgesia thus promoting faster awakening and cooperation and encouraging active movement even in patients on mechanical ventilation

For muscle strengthening and reducing atrophy physiotherapy is often combined with peripheral transcutaneous electrical stimulation of skeletal muscles With electrical stimulation muscle strength can be increase in non-critically ill patients by using stimulation protocols that do not induce muscle fatigue

Electrical stimulation can also alter muscle functionality by decreasing the proportion of fast glycolytic fibers type II which are predominant in less active individuals with predominantly sedentary lifestyles in favor of more endurance-oriented slow-contracting muscle fibers type I fast-to-slow-transition These changes depend significantly on the selected stimulation parameters stimulation duration and muscle innervation Similarly in critically ill patients two consecutive skeletal muscle biopsies performed between the 5th and 15th day of hospitalization revealed a significant decrease in endurance slow-contracting fibers

Electrical stimulation is a promising method for preventing critical illness myopathy but it has certain limitations Studies have not demonstrated its effectiveness in critically ill patients when started within the first seven days of treatment and have not been effective in very acute conditions Electrical stimulation can induce intense and visible muscle contractions in only 75-80 of critically ill patients possibly due to tissue edema over the muscles acting as insulation as the depth of electrical stimulation is limited Furthermore electrical stimulation is a painful method and pain assessment is more challenging in critically ill patients compared to the general population Therefore the selection of parameters used in muscle electrical stimulation in critically ill patients is extremely important

To accurately assess the effectiveness of electrical stimulation muscle thickness assessment using ultrasound and muscle strength assessment using manual muscle testing are employed The most common scale used for muscle strength assessment is the Medical Research Council MRC scale where less than 48 points out of a maximum of 60 points or an average score of less than 4 define ICU-AW ICU-AW encompasses both neuro- and myopathy in critically ill patients

Biphasic symmetric electrical stimulation with a frequency between 30-40 Hz pulse duration of 03 msec with 6 sec on and 6-12 sec off and a total duration of 45-55 minutes has been shown to be the most effective Patients who received electrical stimulation in addition to standard rehabilitation treatment had significantly greater muscle strength according to the MRC scale compared to patients who did not receive electrical stimulation Moreover we observed significantly shorter weaning from mechanical ventilation in patients who underwent muscle electrical stimulation

13 Transcutaneous Functional Muscle Magnetic Stimulation Transcutaneous Functional Muscle Magnetic Stimulation FMS differs from electrical stimulation in that it utilizes a magnetic applicator instead of two or more electrodes for muscle tissue stimulation and is significantly less painful An electric coil installed in the applicator generates a magnetic field that propagates into space The magnetic field also penetrates the human body where it induces electric currents These induced currents are electrical stimuli that much like electrical stimulation artificially propagate a signal along a nerve cell neuron and thereby cause muscle contraction Despite the same triggering mechanism of the electric signal in the nerve cell the method of energy delivery differs Thus FMS is not limited to acting solely on surface structures which is one of the main drawbacks of electrical stimulation as it rarely reaches structures deeper than 12 mm 38 Unlike electrical stimulation FMS penetrate deep into the body without direct contact of the applicator with the skin allowing magnetic stimulation to be performed even through clothing bandages or on injured or sensitive skin Additionally in favor of FMS it does not cause a high concentration of electric current at the point of entry into the body through the skin hence causing no pain

FMS prevents inactivation atrophy of skeletal muscles as demonstrated in the mobilized limb of rats Transcutaneous FMS of the quadriceps via the femoral nerve is a safe and painless method even when applied to humans At a stimulation frequency of 30Hz and a magnetic field of 16 T it is capable of generating approximately 725 of the maximal spontaneous contraction force of the quadriceps In patients with COPD quadriceps FMS increased spontaneous contraction force by 17 compared to the control group and improved quality of life Patients with COPD tolerate quadriceps FMS well as it does not affect oxidative stress in muscles but does increase the size of slow-twitch muscle fibers

In intensive care medicine magnetic stimulation has been primarily used for diagnostic purposes in assessing diaphragm function peripheral muscle strength assessment and transcranial electrical stimulation as a diagnostic tool and therapeutic stimulation of brain cells With the development of modern transcutaneous magnetic stimulators the possibility arises for their use in intensive care medicine for therapeutic purposes such as preventing critical illness myopathy To date no research has been conducted on the use and effectiveness of magnetic stimulation of peripheral muscles in critically ill individuals

14 Diagnosis of ICU-AW Currently there is no single standardized diagnostic criteria to confirm the presence of ICU-AW Clinically muscle strength is assessed in lightly sedated participating patients To raise suspicion of ICU-AW clinical assessment of muscle strength is commonly performed using a modified MRC scale This involves manual muscle testing assessing shoulder abduction elbow flexion and wrist extension for upper limbs and hip flexion knee extension and ankle dorsiflexion for lower limbs The maximum total score of all assessments is 60 A score of 48 or less or an average score of less than 4 may raise clinical suspicion of ICU-AW and associated complications Confirming the existence of ICU-AW often requires the use of invasive diagnostic techniques such as electromyography electroneurography and histomorphological and molecular biological analyses of muscle and nerve biopsy samples These techniques are considered the gold standard for diagnosis Muscle and nerve biopsies can reveal structural anomalies although these procedures are quite invasive and do not always provide a definitive diagnosis for ICU-AW nevertheless they are crucial in identifying muscle atrophy It was demonstrated through muscle biopsy that patients with clinical and electrophysiological patterns of ICU-AW often exhibit myopathic changes Muscle biopsies for demonstrating ICU-AW are most commonly taken from the deltoid muscle or the lateral head of the quadriceps femoris muscle 23
2 Purpose of the study

The purpose of the study is to investigate the effect of FMS on the development of ICU-AW The main objectives of the proposed research are

1 To evaluate the feasibility of FMS in critically ill patients
2 To assess the effectiveness of FMS in preventing atrophy and weakness of skeletal muscles in critically ill patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None